Derma Sciences Cmn (DSCI) 4.01 $DSCI
Why Derma Sciences (DSCI) Could Be Positioned for a Surge
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:35AM CDT
Derma Sciences (DSCI) has a decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
DSCI: 4.01 (+0.02)
Can The Uptrend Continue for Derma Sciences (DSCI)?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:56AM CDT
Investors certainly have to be happy with Derma Sciences Inc (DSCI) and its short term performance
DSCI: 4.01 (+0.02)
Derma Sciences reports 1Q loss
Automated Insights - Wed May 11, 6:37AM CDT
PRINCETON, N.J. (AP) _ Derma Sciences Inc. (DSCI) on Wednesday reported a loss of $1.8 million in its first quarter.
DSCI: 4.01 (+0.02)
Derma Sciences Reports 2016 First Quarter Financial Results
BusinessWire - Wed May 11, 6:30AM CDT
--Conference call begins at 11:00 a.m. Eastern Time today
DSCI: 4.01 (+0.02)
Research and Markets -- European Advanced Wound Care Market Analysis - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Shire, Organogenesis, Derma Sciences
PR Newswire Europe - Fri May 06, 2:11PM CDT
DUBLIN, May 6, 2016 /PRNewswire/ --
DSCI: 4.01 (+0.02)
Derma Sciences to Hold First Quarter Financial Results Conference Call on May 11th
BusinessWire - Fri May 06, 1:31PM CDT
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on May 11, 2016 to discuss the financial results for the first quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
DSCI: 4.01 (+0.02)
Derma Sciences Announces AMNIOEXCEL(R) Is Now Eligible for Reimbursement by Medicare Administrative Contractor CGS
BusinessWire - Wed Apr 27, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that CGS Administrators, LLC (CGS), a Medicare Administrative Contractor (MAC) for Parts A and B serving Kentucky and Ohio, has updated its local coverage determination (LCD) for cellular or tissue-based products (CTPs) of the lower extremity. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for reimbursement coverage with appropriate documentation of medical necessity for the treatment of chronic wounds of the lower extremity, including both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Coverage is effective as of April 1, 2016. CGS is the sixth MAC to issue local coverage determinations for AMNIOEXCEL(R).
DSCI: 4.01 (+0.02)
Mediaplanet and Hope For The Warriors Joins Forces With Industry Leaders To Raise Support for the Limb Loss Community in Mediaplanet's "Amputee Awareness" Campaign
PRWeb - Wed Apr 20, 12:01PM CDT
With the added support of The Amputee Coalition, runway model Rebekah Marine, American Academy of Orthotists & Prosthetics, LIM Innovations, UC San Diego's Human Research Protections Program (HRPP), Derma Sciences, BionX Medical Technologies and many more, Amputee Awareness aims to educate readers, raise awareness and offer support to those who belong to, or work with the limb loss community- reminding them that they are not alone and helping them to live a full, productive life.
DSCI: 4.01 (+0.02)
Medical Products Companies Tap Into $50 Billion U.S. Government GSA Supply Program
ACCESSWIRE - Wed Mar 16, 7:30AM CDT
REDONDO BEACH, CA / ACCESSWIRE / March 16, 2016 / Last week, BioLargo, Inc. (OTC: BLGO), best known for the AOS Filter that has demonstrated the highest impact and lowest cost of any known water treatment technology, announced that the U.S. government had awarded them a five-year General Services Administration and VA Schedule supply contract, under schedule 65IIA for medical equipment and supplies. This contract award is significant because it opens up an important selling channel for the company's current odor and moisture control products as well as future products that will include its Advanced Wound Care Products when they are approved by the FDA. The GSA Schedules program is the premier acquisition vehicle in government with approximately $50 Billion a year in spending for a broad spectrum of products.
DSCI: 4.01 (+0.02), SNN: 34.65 (+0.38), VCEL: 2.29 (+0.06), ALQA: 1.14 (-0.01)
Derma Sciences Reports 2015 Fourth Quarter and Full Year Financial Results
BusinessWire - Wed Mar 16, 6:30AM CDT
--Conference call begins at 11:00 a.m. Eastern Time today
DSCI: 4.01 (+0.02)
Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 16th
BusinessWire - Thu Mar 10, 8:52AM CST
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on Wednesday, March 16, 2016 to discuss the financial results for the fourth quarter of 2015. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
DSCI: 4.01 (+0.02)
Findings from Multicenter Study Comparing Derma Sciences' AMNIOEXCEL(R) Against Standard-of-Care for Treating Diabetic Foot Ulcers Published in WOUNDS, a Leading Peer-Reviewed Journal
BusinessWire - Mon Mar 07, 6:30AM CST
--Findings will enhance efforts to gain positive coverage decisions from three remaining Medicare Administrative Contractors
DSCI: 4.01 (+0.02)
STAAR Surgical Posts Break-Even Q4 Earnings, Sales Rise
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 8:50AM CST
STAAR Surgical Company (STAA) reported breakeven (including stock-based compensation) in the fourth quarter of 2015, which was narrower than the Zacks Consensus Estimate of a loss of 2 cents.
DSCI: 4.01 (+0.02), STAA: 5.62 (+0.36), HSIC: 177.61 (+2.66), COO: 166.59 (+2.04)
Derma Sciences' AMNIOEXCEL(R) Now Eligible for Reimbursement by Medicare Administrative Contractor WPS
BusinessWire - Thu Mar 03, 7:30AM CST
Derma Sciences, Inc. (Nasdaq SCI), a tissue regeneration company focused on advanced wound and burn care, announces that WPS Government Health Administrators (WPS), a Medicare Administrative Contractor (MAC) for Part B serving States primarily in the Midwest and National MAC for Jurisdiction 5, has retired its local coverage determination (LCD) for cellular or tissue-based products (CTPs) effective March 1, 2016. WPS now considers CTPs to be a commonly used tool for treating chronic wounds. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for coverage with appropriate documentation of medical necessity as a second-line therapy following standard wound care treatment.
DSCI: 4.01 (+0.02)
Becton, Dickinson Beats Q1 Earnings, FY16 View Raised
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 9:40AM CST
Becton, Dickinson and Company (BDX), popularly known as BD, reported first-quarter fiscal 2016 earnings of $1.96 per share, which beat the Zacks Consensus Estimate by 12 cents.
DSCI: 4.01 (+0.02), BDX: 172.19 (+2.22), STAA: 5.62 (+0.36), PDCO: 48.46 (+0.56)
CONMED Beats Q4 Earnings & Sales, FY16 View Impressive
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 10:15AM CST
CONMED Corp (CNMD) reported adjusted earnings of 52 cents per share, which beat the Zacks Consensus Estimate by a penny.
DSCI: 4.01 (+0.02), STAA: 5.62 (+0.36), CNMD: 45.50 (+0.98), OCLS: 0.83 (unch)
BioLargo Closes Financing To Advance Its Novel Wound Care Products
ACCESSWIRE - Wed Jan 20, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 20, 2016 / BioLargo, Inc. (OTC: BLGO) recently announced that its subsidiary, Clyra Medical Technologies, secured a $5.75 million financing package for Its Advanced Wound Care Products. Cash of $750,000 is earmarked for FDA Application and approval, and a $5 million line of credit is dedicated to commercialization once FDA approval is complete.
DSCI: 4.01 (+0.02), SNN: 34.65 (+0.38), VCEL: 2.29 (+0.06), OSIR: 5.50 (+0.30)
Global Compression Therapy Analysis and Market Forecasts Report 2015-2021 - Sigvaris, BSN Medical, Medi, and Medtronic currently dominate the global advanced dressings market
M2 - Mon Jan 18, 6:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvlbl2/medipoint) has announced the addition of the "MediPoint: Compression Therapy - Global Analysis and Market Forecasts" report to their offering. The overall compression therapy market has been estimated in this report, which covers the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India (10MM) up to 2021. The report provides an investigation of unmet needs, future adoption trends and compound annual growth rates (CAGR) for each geography and market segment. In addition, this report presents the current market drivers and barriers which will influence the future market growth of compression therapy in the 10MM. Compression therapy products, especially static compression devices, have become the standard in the treatment of venous conditions, such as deep vein thrombosis (DVT), varicose veins, and venous leg ulcers, and lymphatic disorders, such as primary and secondary lymphedema. While elastic stockings and compression bandaging have played important roles in providing effective therapies, newer modes of static compression such as custom garments and adjustable products have been introduced to ease patient burden and improve treatment compliance. Pneumatic compression devices have similarly advanced, despite their lower adoption rates. Segmented pumps with tunable pressure characteristics have joined the ranks of simpler devices with single outputs for single inflatable chambers in the treatment of venous and lymphatic conditions. Although pneumatic compression has not quite been an arena of rapid innovation, some manufacturers have developed advanced pump systems that deliver complex pressure profiles to the affected areas of the patients' bodies. This report focuses on both static and pneumatic compression market categories. Key Questions Answered - What is the current and future market outlook for compression therapy products in the developed and emerging markets? What trends are affecting the global compression therapy market? - Which are the key, high growth markets? What compression therapy segments are growing the fastest? - What are the unmet needs? What is the scope for more innovation and what are the end-users looking for in their products? - What are some of the newer innovations that may fulfill these unmet needs? What are the physician perceptions and market outlooks? - What percent of global revenue are from emerging markets? How will this change in the future? - Sigvaris, BSN Medical, Medi, and Medtronic currently dominate the global advanced dressings market. What are their market shares in the major global economies and which companies constitute the remainder of the market? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers and Barriers 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 13 Market Outlooks by Geography 14 Appendix Companies Mentioned - Covidien (Medtronic) - Sigvaris - BSN Medical - Medi - Innothera - 3M Health Care - Thuasne - Paul Hartmann - Mego Afek - Medline Industries - ArjoHuntleigh (Getinge) - DJO Global - Lohmann & Rauscher - Venosan (Salzmann) - Sanyleg (Mimosa) - Juzo - Daesung Maref - Bio Compression Systems - Smith & Nephew - Molnlycke Health Care - Gloria Med - B. Braun - Alcare - Derma Sciences - Laboratoires Urgo - Systagenix (Acelity) - Muranaka Medical Instruments - ConvaTec - Xiamen Senyang - Guangzhou Yihao Electronic Technology - Talley Group - Cardinal Health - Tactile Medical - Devon Medical For more information visit http://www.researchandmarkets.com/research/jvlbl2/medipoint
DSCI: 4.01 (+0.02), SNN: 34.65 (+0.38), MDT: 85.77 (+1.51)
Why Derma Sciences (DSCI) Could Be Positioned for a Surge
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:35AM CDT
Derma Sciences (DSCI) has a decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
DSCI: 4.01 (+0.02)
Can The Uptrend Continue for Derma Sciences (DSCI)?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:56AM CDT
Investors certainly have to be happy with Derma Sciences Inc (DSCI) and its short term performance
DSCI: 4.01 (+0.02)
Derma Sciences reports 1Q loss
Automated Insights - Wed May 11, 6:37AM CDT
PRINCETON, N.J. (AP) _ Derma Sciences Inc. (DSCI) on Wednesday reported a loss of $1.8 million in its first quarter.
DSCI: 4.01 (+0.02)
Derma Sciences Reports 2016 First Quarter Financial Results
BusinessWire - Wed May 11, 6:30AM CDT
--Conference call begins at 11:00 a.m. Eastern Time today
DSCI: 4.01 (+0.02)
Research and Markets -- European Advanced Wound Care Market Analysis - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Shire, Organogenesis, Derma Sciences
PR Newswire Europe - Fri May 06, 2:11PM CDT
DUBLIN, May 6, 2016 /PRNewswire/ --
DSCI: 4.01 (+0.02)
Derma Sciences to Hold First Quarter Financial Results Conference Call on May 11th
BusinessWire - Fri May 06, 1:31PM CDT
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on May 11, 2016 to discuss the financial results for the first quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones. DSCI: 4.01 (+0.02)
Derma Sciences Announces AMNIOEXCEL(R) Is Now Eligible for Reimbursement by Medicare Administrative Contractor CGS
BusinessWire - Wed Apr 27, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that CGS Administrators, LLC (CGS), a Medicare Administrative Contractor (MAC) for Parts A and B serving Kentucky and Ohio, has updated its local coverage determination (LCD) for cellular or tissue-based products (CTPs) of the lower extremity. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for reimbursement coverage with appropriate documentation of medical necessity for the treatment of chronic wounds of the lower extremity, including both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Coverage is effective as of April 1, 2016. CGS is the sixth MAC to issue local coverage determinations for AMNIOEXCEL(R).
DSCI: 4.01 (+0.02)
Mediaplanet and Hope For The Warriors Joins Forces With Industry Leaders To Raise Support for the Limb Loss Community in Mediaplanet's "Amputee Awareness" Campaign
PRWeb - Wed Apr 20, 12:01PM CDT
With the added support of The Amputee Coalition, runway model Rebekah Marine, American Academy of Orthotists & Prosthetics, LIM Innovations, UC San Diego's Human Research Protections Program (HRPP), Derma Sciences, BionX Medical Technologies and many more, Amputee Awareness aims to educate readers, raise awareness and offer support to those who belong to, or work with the limb loss community- reminding them that they are not alone and helping them to live a full, productive life.
DSCI: 4.01 (+0.02)
Medical Products Companies Tap Into $50 Billion U.S. Government GSA Supply Program
ACCESSWIRE - Wed Mar 16, 7:30AM CDT
REDONDO BEACH, CA / ACCESSWIRE / March 16, 2016 / Last week, BioLargo, Inc. (OTC: BLGO), best known for the AOS Filter that has demonstrated the highest impact and lowest cost of any known water treatment technology, announced that the U.S. government had awarded them a five-year General Services Administration and VA Schedule supply contract, under schedule 65IIA for medical equipment and supplies. This contract award is significant because it opens up an important selling channel for the company's current odor and moisture control products as well as future products that will include its Advanced Wound Care Products when they are approved by the FDA. The GSA Schedules program is the premier acquisition vehicle in government with approximately $50 Billion a year in spending for a broad spectrum of products.
DSCI: 4.01 (+0.02), SNN: 34.65 (+0.38), VCEL: 2.29 (+0.06), ALQA: 1.14 (-0.01)
Derma Sciences Reports 2015 Fourth Quarter and Full Year Financial Results
BusinessWire - Wed Mar 16, 6:30AM CDT
--Conference call begins at 11:00 a.m. Eastern Time today
DSCI: 4.01 (+0.02)
Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 16th
BusinessWire - Thu Mar 10, 8:52AM CST
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on Wednesday, March 16, 2016 to discuss the financial results for the fourth quarter of 2015. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
DSCI: 4.01 (+0.02)
Findings from Multicenter Study Comparing Derma Sciences' AMNIOEXCEL(R) Against Standard-of-Care for Treating Diabetic Foot Ulcers Published in WOUNDS, a Leading Peer-Reviewed Journal
BusinessWire - Mon Mar 07, 6:30AM CST
--Findings will enhance efforts to gain positive coverage decisions from three remaining Medicare Administrative Contractors
DSCI: 4.01 (+0.02)
STAAR Surgical Posts Break-Even Q4 Earnings, Sales Rise
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 8:50AM CST
STAAR Surgical Company (STAA) reported breakeven (including stock-based compensation) in the fourth quarter of 2015, which was narrower than the Zacks Consensus Estimate of a loss of 2 cents.
DSCI: 4.01 (+0.02), STAA: 5.62 (+0.36), HSIC: 177.61 (+2.66), COO: 166.59 (+2.04)
Derma Sciences' AMNIOEXCEL(R) Now Eligible for Reimbursement by Medicare Administrative Contractor WPS
BusinessWire - Thu Mar 03, 7:30AM CST
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound and burn care, announces that WPS Government Health Administrators (WPS), a Medicare Administrative Contractor (MAC) for Part B serving States primarily in the Midwest and National MAC for Jurisdiction 5, has retired its local coverage determination (LCD) for cellular or tissue-based products (CTPs) effective March 1, 2016. WPS now considers CTPs to be a commonly used tool for treating chronic wounds. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for coverage with appropriate documentation of medical necessity as a second-line therapy following standard wound care treatment. DSCI: 4.01 (+0.02)
Becton, Dickinson Beats Q1 Earnings, FY16 View Raised
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 9:40AM CST
Becton, Dickinson and Company (BDX), popularly known as BD, reported first-quarter fiscal 2016 earnings of $1.96 per share, which beat the Zacks Consensus Estimate by 12 cents.
DSCI: 4.01 (+0.02), BDX: 172.19 (+2.22), STAA: 5.62 (+0.36), PDCO: 48.46 (+0.56)
CONMED Beats Q4 Earnings & Sales, FY16 View Impressive
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 10:15AM CST
CONMED Corp (CNMD) reported adjusted earnings of 52 cents per share, which beat the Zacks Consensus Estimate by a penny.
DSCI: 4.01 (+0.02), STAA: 5.62 (+0.36), CNMD: 45.50 (+0.98), OCLS: 0.83 (unch)
BioLargo Closes Financing To Advance Its Novel Wound Care Products
ACCESSWIRE - Wed Jan 20, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 20, 2016 / BioLargo, Inc. (OTC: BLGO) recently announced that its subsidiary, Clyra Medical Technologies, secured a $5.75 million financing package for Its Advanced Wound Care Products. Cash of $750,000 is earmarked for FDA Application and approval, and a $5 million line of credit is dedicated to commercialization once FDA approval is complete.
DSCI: 4.01 (+0.02), SNN: 34.65 (+0.38), VCEL: 2.29 (+0.06), OSIR: 5.50 (+0.30)
Global Compression Therapy Analysis and Market Forecasts Report 2015-2021 - Sigvaris, BSN Medical, Medi, and Medtronic currently dominate the global advanced dressings market
M2 - Mon Jan 18, 6:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvlbl2/medipoint) has announced the addition of the "MediPoint: Compression Therapy - Global Analysis and Market Forecasts" report to their offering. The overall compression therapy market has been estimated in this report, which covers the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India (10MM) up to 2021. The report provides an investigation of unmet needs, future adoption trends and compound annual growth rates (CAGR) for each geography and market segment. In addition, this report presents the current market drivers and barriers which will influence the future market growth of compression therapy in the 10MM. Compression therapy products, especially static compression devices, have become the standard in the treatment of venous conditions, such as deep vein thrombosis (DVT), varicose veins, and venous leg ulcers, and lymphatic disorders, such as primary and secondary lymphedema. While elastic stockings and compression bandaging have played important roles in providing effective therapies, newer modes of static compression such as custom garments and adjustable products have been introduced to ease patient burden and improve treatment compliance. Pneumatic compression devices have similarly advanced, despite their lower adoption rates. Segmented pumps with tunable pressure characteristics have joined the ranks of simpler devices with single outputs for single inflatable chambers in the treatment of venous and lymphatic conditions. Although pneumatic compression has not quite been an arena of rapid innovation, some manufacturers have developed advanced pump systems that deliver complex pressure profiles to the affected areas of the patients' bodies. This report focuses on both static and pneumatic compression market categories. Key Questions Answered - What is the current and future market outlook for compression therapy products in the developed and emerging markets? What trends are affecting the global compression therapy market? - Which are the key, high growth markets? What compression therapy segments are growing the fastest? - What are the unmet needs? What is the scope for more innovation and what are the end-users looking for in their products? - What are some of the newer innovations that may fulfill these unmet needs? What are the physician perceptions and market outlooks? - What percent of global revenue are from emerging markets? How will this change in the future? - Sigvaris, BSN Medical, Medi, and Medtronic currently dominate the global advanced dressings market. What are their market shares in the major global economies and which companies constitute the remainder of the market? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers and Barriers 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 13 Market Outlooks by Geography 14 Appendix Companies Mentioned - Covidien (Medtronic) - Sigvaris - BSN Medical - Medi - Innothera - 3M Health Care - Thuasne - Paul Hartmann - Mego Afek - Medline Industries - ArjoHuntleigh (Getinge) - DJO Global - Lohmann & Rauscher - Venosan (Salzmann) - Sanyleg (Mimosa) - Juzo - Daesung Maref - Bio Compression Systems - Smith & Nephew - Molnlycke Health Care - Gloria Med - B. Braun - Alcare - Derma Sciences - Laboratoires Urgo - Systagenix (Acelity) - Muranaka Medical Instruments - ConvaTec - Xiamen Senyang - Guangzhou Yihao Electronic Technology - Talley Group - Cardinal Health - Tactile Medical - Devon Medical For more information visit http://www.researchandmarkets.com/research/jvlbl2/medipoint
DSCI: 4.01 (+0.02), SNN: 34.65 (+0.38), MDT: 85.77 (+1.51)
